MedPath

TOLMAR INC

TOLMAR INC logo
🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

Phase 4
Active, not recruiting
Conditions
Hypogonadism
Interventions
First Posted Date
2024-04-26
Last Posted Date
2024-10-22
Lead Sponsor
Tolmar Inc.
Target Recruit Count
110
Registration Number
NCT06385509
Locations
🇺🇸

Alliance for Multispecialty Research, Norfolk, Virginia, United States

🇺🇸

Clinical Trials Research, Lincoln, California, United States

🇺🇸

Long Beach Research Institute, LLC, Long Beach, California, United States

and more 21 locations

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

First Posted Date
2022-12-09
Last Posted Date
2025-05-02
Lead Sponsor
Tolmar Inc.
Target Recruit Count
250
Registration Number
NCT05645536
Locations
🇺🇸

Texas Oncology - Central South, Austin, Texas, United States

🇧🇷

Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil

🇺🇸

Marin Cancer Care, Inc., Greenbrae, California, United States

and more 22 locations

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer

First Posted Date
2021-05-28
Last Posted Date
2025-05-18
Lead Sponsor
Tolmar Inc.
Target Recruit Count
250
Registration Number
NCT04906395
Locations
🇺🇸

Texas Oncology- Deke Slayton Cancer Center, Webster, Texas, United States

🇧🇷

Hospital Araujo Jorge, Goiania, Goias, Brazil

🇺🇸

Marin Cancer Care, Inc, Greenbrae, California, United States

and more 114 locations

BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis

Phase 1
Completed
Conditions
Scalp Psoriasis
Interventions
First Posted Date
2017-04-20
Last Posted Date
2018-03-07
Lead Sponsor
Tolmar Inc.
Target Recruit Count
699
Registration Number
NCT03122353
Locations
🇺🇸

Site 29, Fremont, California, United States

🇺🇸

Site 18, Sherman Oaks, California, United States

🇺🇸

Site 01, Brandon, Florida, United States

and more 31 locations

Study of Leuprolide Acetate Injectable Suspension in the Treatment of Central Precocious Puberty

Phase 3
Completed
Conditions
Precocious Puberty, Central
Interventions
First Posted Date
2015-05-25
Last Posted Date
2020-06-02
Lead Sponsor
Tolmar Inc.
Target Recruit Count
64
Registration Number
NCT02452931
Locations
🇺🇸

University of Oklahoma College of Medicine, Tulsa, Oklahoma, United States

🇨🇦

McGill University Health Centre, Montreal, Quebec, Canada

🇳🇿

The Liggins Institute, University of Auckland, Auckland, New Zealand

and more 17 locations
© Copyright 2025. All Rights Reserved by MedPath